Latest Content

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

GEODIS completed 86 international trial shipments using recyclable paper-based thermal covers, marking a credible step forward in sustainable pharmaceutical airfreight packaging.

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions.

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it.

In this week's Pharma Pulse, UPS commits $48 million to cold chain infrastructure, AbbVie moves to acquire Apogee Therapeutics in a $10.9 billion deal, and more.

In this special episode of Pharma Pulse, Rohit Tripathi breaks down how companies should be scenario planning ahead of the first USMCA joint review which begins on July 1.

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.

A US Section 301 probe into Germany's drug pricing could bring tariffs on APIs and finished drugs, raising new supply chain and pricing risks.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027.